---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-097094"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2026-08-14T20:06:03+00:00"
generated_at: "2026-08-14T20:12:14.910216+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Quoin Q2 net loss $5.4M; FDA clears first-ever IND for Peeling Skin Syndrome

## Summary
- Q2 2026 net loss $5.4M vs $3.7M in Q2 2025; six-month loss $10.4M vs $7.5M.
- Cash, equivalents, and marketable securities $10.8M as of June 30, 2026; funds operations into 2027.
- FDA conditionally approved QYLEKI as brand name for QRX003 (Netherton Syndrome) on June 23, 2026.
- FDA cleared IND for QRX003 in Peeling Skin Syndrome on July 9, 2026; Phase 2/3 study to start 2H 2026.
- USPTO issued Notice of Allowance for patent covering combination treatment for Netherton Syndrome on June 30, 2026.

## SEC filing metadata
- accession: 0001104659-26-097094
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2026-08-14T20:06:03+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465926097094/0001104659-26-097094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465926097094/tm2623115d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-097094
- JSON: https://secwatch.observer/filing/0001104659-26-097094.json
- Plain text: https://secwatch.observer/filing/0001104659-26-097094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.